GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).